Cell & Gene
Therapy CTDMO

Contract Testing, Development,
and Manufacturing Services for Advanced Therapies.

Connect with an expert

Delivering the Future
of Medicine

We are a global contract testing, development and manufacturing organization, (CTDMO). We enable the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. Our vision is that one day, every drug can be made, and every disease can be treated.

Learn More About Us

Innovative and Transformative Services

For more than 20 years, we have been working with pioneers in advanced therapies to help them successfully discover, develop, manufacture and release their products for patient use.

Contract Testing

Proven analytical method development, lot release testing, viral clearance, stability, and more.

Learn More
WuXi Advanced Therapies_Testing Services
Process Development

Expert and flexible approaches to develop, scale, and optimize your processes and methods.

Learn More
WuXi Advanced Therapies_PD Home Page
IND Enabling Studies

Optimize processes, ensure GMP readiness, and secure data required for your IND submission.

Learn More
WuXi Advanced Therapies_successful IND submission
Clinical Manufacturing

Phase appropriate approaches that accelerate timelines and ensure quality clinical production.

Learn More
WuXi Advanced Therapies Plasmid Production
Commercial Manufacturing

High-quality, high-volume capacity, infrastructure, logistics, and systems which have passed inspection.

Learn More
WuXi Advanced Therapies Plasmid Manufacturing

Our
Capabilities

Expertise
Facilities
Quality
Regulatory
Supply Chain

Modalities and Therapeutic Areas

Our experience and services cover CAR-T, T-Cell, TIL, MSC, AAV, Lenti, mAbs, Vaccines and other common advanced therapies.

Autologous
Allogeneic
Monoclonal Antibodies
Vaccines
Viral Vectors

Let's get started

Tell us about your program. Connect with experts.

Start Now

Articles & Events

Advanced Therapies Acquired by Altaris

Philadelphia, U.S. and Oxford, U.K. sites and capabilities spun out of WuXi AppTec We are excited to share that Altaris completed its acquisition of Advanced Therapies U.S. and OXGENE (together “Advanced Therapies”) on 7 March 2025. Advanced Therapies is now fully owned by Altaris and headquartered in the United States. Altaris is an investment firm […]

Apr 1
London, UK
BioTrinity 2025
Apr 3
Munich, Germany
11th Immunotherapy of Cancer Conference
See All Events
Ameba Creative StudioAmeba Creative Studio